Loading...
Docoh
Log in Free sign up

Applied Genetic Technologies (AGTC)

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

Company profile

Ticker
AGTC
Exchange
NASDAQ
Website
www.agtc.com
CEO
Susan Washer
Employees
Incorporated
Delaware
Location
Florida
Fiscal year end
Jun 30
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
0001273636
Corporate docs

AGTC stock data

News

From Benzinga Pro
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
26 Jul 22
AGTC Receives Positive Type C Meeting Feedback From The FDA For The Company's Design And Operating Procedures Of Its Planned cGMP Manufacturing Facility
26 Jul 22
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the
Stocks That Hit 52-Week Lows On Friday
15 Jul 22
On Friday, 137 stocks made new 52-week lows.
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
14 Jul 22
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Jul 22

Press releases

From Benzinga Pro
AGTC to Participate in Upcoming Investor Conferences
1 Aug 22
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the
AGTC Announces Pricing of $10 Million Underwritten Public Offering
12 Jul 22
GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the
AGTC Announces Proposed Underwritten Public Offering
12 Jul 22
GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
7 Jul 22
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
9 Jun 22

Analyst ratings and price targets

Last 3 months
Chardan Capital
Maintains
Buy
$5.00
18 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 May 22
12 Aug 22
30 Jun 23

Financial summary

Financial statements Chart AGTC financial data
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jun 21 Jun 20 Jun 19 Jun 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 67.85M 67.85M 67.85M 67.85M 67.85M 67.85M
Cash burn (monthly) 1.64M 1.81M 4.53M 5.19M 4.67M 5.08M
Cash used (since last report) 7.25M 7.99M 20.01M 22.93M 20.62M 22.44M
Cash remaining 60.6M 59.86M 47.84M 44.92M 47.23M 45.41M
Runway (months of cash) 36.9 33.1 10.6 8.7 10.1 8.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

AGTC insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Stephen W Potter Common Stock Sell Dispose S No No 0.7745 8,070 6.25K 55,883
27 May 22 Gerald Anthony Reynolds Common Stock Sell Dispose S No No 0.8452 3,994 3.38K 21,006
18 Feb 22 Susan B. Washer Common Stock Sell Dispose S No No 2.18 9,950 21.69K 143,021
18 Feb 22 Susan B. Washer Common Stock Option exercise Acquire M No No 0.35 120,686 42.24K 152,971
18 Feb 22 Susan B. Washer Stock Option Common Stock Option exercise Dispose M No No 0.35 120,686 42.24K 0
13 Dec 21 Hope DOyley-Gay Stock Option Common Stock Grant Acquire A No No 2.02 180,000 363.6K 180,000
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

AGTC institutional ownership history Ownership history
36.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 59 60 -1.7%
Opened positions 10 9 +11.1%
Closed positions 11 18 -38.9%
Increased positions 15 12 +25.0%
Reduced positions 15 20 -25.0%
13F shares Current Prev Q Change
Total value 27.29M 70.69M -61.4%
Total shares 18.46M 17.13M +7.8%
Total puts 49.5K 89K -44.4%
Total calls 50.4K 48.8K +3.3%
Total put/call ratio 1.0 1.8 -46.1%
Largest owners Shares Value Change
Cantor Fitzgerald, L. P. 2.36M $2.52M NEW
Vanguard 1.98M $2.12M +14.4%
Millennium Management 1.65M $1.76M +7.5%
Portolan Capital Management 1.61M $1.72M +18.0%
Interwest Partners Viii 1.4M $2.67M 0.0%
Interwest Venture Management 1.4M $1.5M 0.0%
Intersouth Partners Vi 1.21M $4.97M 0.0%
BLK Blackrock 1.12M $1.2M +1.1%
Sabby Management 970.06K $1.04M NEW
Integrated Core Strategies 717.36K $2.93M 0.0%
Largest transactions Shares Bought/sold Change
Cantor Fitzgerald, L. P. 2.36M +2.36M NEW
Empery Asset Management 100K -1.87M -94.9%
Sabby Management 970.06K +970.06K NEW
Altrinsic Global Advisors 0 -376.9K EXIT
Vanguard 1.98M +248.82K +14.4%
Portolan Capital Management 1.61M +244.9K +18.0%
MS Morgan Stanley 43.04K -209.83K -83.0%
Two Sigma Advisers 117.73K -172.5K -59.4%
Ci Investments 161.8K +161.8K NEW
Assenagon Asset Management 277.66K -152.9K -35.5%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Biogen • Ocugen • IVERIC bio • Adverum Biotechnologies • Benitec Biopharma • Allergan • uniQure • Regenxbio • Spark Therapeutics • Voyager Therapeutics
Management Discussion
  • During the years ended June 30, 2021 and 2020, we recognized total revenue of $0.5 million and $2.5 million, respectively.
  • Effective April 13, 2021, we entered into a license agreement with a third party whereby we provided nonexclusive rights to our proprietary cone-specific promoter technology for use in the development of two non-competing products. In connection with this agreement, we recognized $0.5 million of license fee revenue during the year ended June 30, 2021.
  • During December 2019, Bionic Sight met a milestone related to clearance of filing of an Investigational New Drug application under its collaboration agreement with us and, as a result, we recognized $2.2 million of non-cash collaboration revenue during the year ended June 30, 2020 in connection with in-kind contributions made since inception of the Bionic Sight collaboration agreement. During the year ended June 30, 2020, we also recorded $0.2 million and $0.1 million of grant revenue and other milestone revenue, respectively.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: afforded, agreed, aninitial, appeal, approach, architectural, ARVO, assay, bid, broader, budget, canhave, chart, clear, coefficient, combat, comply, consecutive, cure, dB, deemed, delisted, delisting, Demographic, diminished, drove, earlier, equivalent, escrow, fact, fewer, fora, fortify, inflation, intent, intraocular, invoice, invoiced, Journal, larger, listing, loglux, meaningful, Nasdaq, paid, panel, perimeter, pressure, prime, proposed, rapidly, regain, reiterated, repeatability, Snellen, Street, substantive, surgical, theofficer, toanofficer, unevaluable, Wall
Removed: advancement, biologic, committee, criterion, decibel, demonstrate, discretion, enable, launch, November, profile, senior, strategy, twenty
From filing 10-Q 2022 Q3
Financial reports
View all
10-Q
2022 Q3
Quarterly report
15 May 22
10-Q
2022 Q2
Quarterly report
14 Feb 22
10-Q
2022 Q1
Quarterly report
9 Nov 21
10-K
2021 FY
Annual report
23 Sep 21
10-Q
2021 Q3
Quarterly report
17 May 21
10-Q
2021 Q2
Quarterly report
11 Feb 21
10-Q
2021 Q1
Quarterly report
16 Nov 20
10-K
2020 FY
Annual report
18 Sep 20
10-Q
2020 Q3
Quarterly report
13 May 20
10-Q
2020 Q2
Quarterly report
5 Feb 20
Current reports
View all
8-K
Departure of Directors or Certain Officers
12 Aug 22
8-K
AGTC Announces Proposed Underwritten Public Offering
14 Jul 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Jun 22
8-K
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
16 May 22
8-K
Entry into a Material Definitive Agreement
9 May 22
8-K
AGTC Announces Proposed Public Offering of Common Stock
23 Mar 22
8-K
Departure of Directors or Certain Officers
2 Mar 22
8-K
Results of Operations and Financial Condition
14 Feb 22
8-K
Regulation FD Disclosure
8 Feb 22
8-K
Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022
11 Jan 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
14 Jul 22
424B5
Prospectus supplement for primary offering
12 Jul 22
424B5
Prospectus supplement for primary offering
23 Mar 22
424B5
Prospectus supplement for primary offering
21 Mar 22
S-8
Registration of securities for employees
23 Sep 21
S-3
Shelf registration
2 Apr 21
424B5
Prospectus supplement for primary offering
29 Jan 21
424B5
Prospectus supplement for primary offering
27 Jan 21
S-8
Registration of securities for employees
18 Sep 20
424B4
Prospectus supplement with pricing info
7 Feb 20
Proxies
View all
DEFA14A
Additional proxy soliciting materials
15 Oct 21
DEF 14A
Definitive proxy
15 Oct 21
DEFA14A
Additional proxy soliciting materials
2 Nov 20
DEF 14A
Definitive proxy
2 Nov 20
DEF 14A
Definitive proxy
4 Nov 19
DEF 14A
Definitive proxy
16 Oct 18
DEF 14A
Definitive proxy
28 Jan 18
DEF 14A
Definitive proxy
12 Jan 17
DEF 14A
Definitive proxy
12 Oct 15
DEF 14A
Definitive proxy
9 Oct 14
Other
View all
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
7 Apr 21
UPLOAD
Letter from SEC
6 Apr 21
EFFECT
Notice of effectiveness
7 Feb 20
CORRESP
Correspondence with SEC
4 Feb 20
CORRESP
Correspondence with SEC
4 Feb 20
UPLOAD
Letter from SEC
3 Feb 20
CT ORDER
Confidential treatment order
16 Jan 20
CT ORDER
Confidential treatment order
3 Jul 18
EFFECT
Notice of effectiveness
20 Jun 18
Ownership
View all
4
APPLIED GENETIC TECHNOLOGIES / Stephen W Potter ownership change
1 Jul 22
4
APPLIED GENETIC TECHNOLOGIES / Gerald Anthony Reynolds ownership change
31 May 22
4
APPLIED GENETIC TECHNOLOGIES / Susan B. Washer ownership change
22 Feb 22
SC 13G
APPLIED GENETIC TECHNOLOGIES / Portolan Capital Management ownership change
15 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / INTERWEST PARTNERS VIII ownership change
14 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Stonepine Capital Management ownership change
11 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Portolan Capital Management ownership change
11 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Empery Asset Management ownership change
19 Jan 22
4
APPLIED GENETIC TECHNOLOGIES / Hope DOyley-Gay ownership change
15 Dec 21
3
APPLIED GENETIC TECHNOLOGIES / Hope DOyley-Gay ownership change
15 Dec 21

Patents

View all
Utility
Recombinant Aav Production In Mammalian Cells
4 Nov 21
The present invention includes methods and compositions for the production of high titer recombinant Adeno-Associated Virus (rAAV) in a variety of mammalian cells.
Utility
Codon Optimized Nucleic Acid Encoding a Retinitis Pigmentosa Gtpase Regulator (RPGR)
10 Jun 21
This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein.
Utility
Promoters, Expression Cassettes, Vectors, Kits, and Methods for the Treatment of Achromatopsia and Other Diseases
27 May 21
The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
Utility
Adeno-associated Virus (Aav) Systems for Treatment of Progranulin Associated Neurodegenerative Diseases or Disorders
20 May 21
The disclosure provides, in part, optimally-modified progranulin (PGRN) cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for neurodegenerative disorders characterized by cognitive disruption, behavioral impairment, and deficient lysosomal storage, including familial frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), neuronal ceroid lipofuscinosis (NCL), or Alzheimer's disease (AD).
Utility
Triple Function Adeno-associated Virus (Aav)vectors for the Treatment of C9ORF72 Associated Diseases
20 May 21
The present disclosure provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of C9ORF72 associated diseases, including ALS and FTD.

Transcripts

View all
2022 Q2
Earnings call transcript
14 Feb 22
2021 Q4
Earnings call transcript
24 Sep 21
2021 Q4
Earnings call transcript
24 Sep 21
2021 Q3
Earnings call transcript
18 May 21
2021 Q2
Earnings call transcript
11 Feb 21
2020 Q4
Earnings call transcript
9 Sep 20
2020 Q3
Earnings call transcript
13 May 20
2007 Q1
Earnings call transcript
9 Jan 20
2020 Q1
Earnings call transcript
13 Nov 19
2019 Q4
Earnings call transcript
26 Sep 19

Reddit threads

View all